ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pneumococcal 21-Valent Conjugate Vaccine

Also written as “V116”, “PCV21 vaccine” and “PCV21”.

Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Anemia, Sickle Cell, led by 2 companies.

Drug pagePneumococcal 21-Valent Conjugate Vaccine: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 23, 202218 company-led studies, 7 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck110 open or runningphase 3since May 23, 2022Nov 18, 2019none ahead
Sanofiits history only77 open or runningphase 3since Oct 10, 2024Oct 10, 2024Dec 1, 2026phase 3 · NCT06838000

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 18, 2019First study: phase 2 study in Pneumonia, PneumococcalFirst studyNCT04168190 · 600 enrolled · United States
  2. Dec 8, 2020Phase 1 study in Pneumococcal InfectionsNCT04665050 · 102 enrolled · Japan
  3. May 23, 2022Phase 3 study in Pneumococcal InfectionsNCT05393037 · 313 enrolled · United States, Belgium, Chile and more
  4. Jun 13, 20222 phase 3 studiesNCT05420961, NCT05425732
  5. Jul 12, 2022Phase 3 study in Pneumococcal InfectionsNCT05464420 · 2,162 enrolled · United States, Austria, Canada and more
  6. Aug 31, 2022Phase 3 study in Pneumonia, PneumococcalNCT05526716 · 1,080 enrolled · United States
  7. Oct 4, 2022Phase 3 study in Pneumococcal InfectionsNCT05569954 · 1,484 enrolled · Argentina, Australia, Colombia and more
  8. Nov 21, 2022Phase 3 study in Pneumococcal InfectionsNCT05633992 · 450 enrolled · Japan
  9. Jan 13, 2023Phase 3 study in Pneumococcal InfectionsNCT05696080 · 518 enrolled · United States, Australia, Canada and more
  10. Dec 11, 2023Phase 3 study in Pneumococcal InfectionsNCT06177912 · 882 enrolled · United States, Canada, Chile and more

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A pneumococcal conjugate vaccine containing 21 different strains of the bacterium Streptococcus pneumoniae, that is used for the prevention of pneumococcal disease”NCIt, by rule
“Pneumococcal 21-Valent Conjugate Vaccine”name, by rule

Studies

All 11 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06177912Pneumococcal Infections · United States, Canada, Chile and more3CompletedFeb 26, 2025882
NCT05696080Pneumococcal Infections · United States, Australia, Canada and more3CompletedFeb 16, 2024518
NCT05633992Pneumococcal Infections · Japan3CompletedMay 24, 2023450
NCT05569954Pneumococcal Infections · Argentina, Australia, Colombia and more3CompletedOct 30, 20231,484
NCT05526716Pneumonia, Pneumococcal · United States3CompletedJun 21, 20231,080
NCT05464420Pneumococcal Infections · United States, Austria, Canada and more3CompletedMay 25, 20232,162
NCT05425732Pneumococcal Infections · United States, Australia, Belgium and more3CompletedMay 18, 20232,663
NCT05420961Pneumonia, Pneumococcal · United States, Canada, France and more3CompletedMay 16, 2023717
NCT05393037Pneumococcal Infections · United States, Belgium, Chile and more3CompletedJul 13, 2023313
NCT04665050Pneumococcal Infections · Japan1CompletedApr 6, 2021102
NCT04168190Pneumonia, Pneumococcal · United States2CompletedJul 12, 2021600

How it is read

Names in the registry

  • “V116”, 11 entries
  • “PCV21 vaccine”, 5 entries
  • “PCV21”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.